We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+102%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$346M
AUM Growth
+$140M
Cap. Flow
+$48.5M
Cap. Flow %
14.01%
Top 10 Hldgs %
48.64%
Holding
51
New
19
Increased
12
Reduced
13
Closed
5

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$15.9M
2
KURA icon
Kura Oncology
KURA
+$9.73M
3
LRMR icon
Larimar Therapeutics
LRMR
+$8.24M
4
IMVT icon
Immunovant
IMVT
+$7.5M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$7.32M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$16.8M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.2M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$8.12M
4
ARVN icon
Arvinas
ARVN
+$6.67M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$4.84M

Sector Composition

Rank Sector Weight
1 Healthcare 91.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
51
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-139,464
Closed -$4.38M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Acuta Capital Partners held 51 positions worth $346M, up 68% from $206M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Acuta Capital Partners deployed $48.5M of net new capital in Q2 2020, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 545,000 shares worth $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $16.8M trimmed.

  • Acuta Capital Partners's largest Q2 2020 buy was Immunomedics Inc: 545,000 shares worth $19.3M.
  • Acuta Capital Partners added most to Kura Oncology in Q2 2020, an estimated $9.73M increase.
  • Acuta Capital Partners's biggest Q2 2020 reduction was Axsome Therapeutics, cutting an estimated $16.8M.
  • Acuta Capital Partners fully exited Aurinia Pharmaceuticals in Q2 2020, selling an estimated $11.2M.
  • Acuta Capital Partners's ten largest holdings make up 49% of its $346M portfolio in Q2 2020.
  • Acuta Capital Partners opened 19 new positions and closed 5 in Q2 2020.
  • Acuta Capital Partners's portfolio value rose 68% quarter-over-quarter to $346M.

Based on Acuta Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.